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Abstract: Drug resistance is a common concern for the development of novel antiviral, antimicrobial and anticancer therapies. To over-
come this problem, several strategies have been developed, many of which involving the theme of this review, the use of structure-based 
drug design (SBDD) approaches. These include the successful design of new compounds that target resistant mutant proteins, as well as 
the development of drugs that target multiple proteins involved in specific biochemical pathways. Finally, drug resistance can also be 
considered in the early stages of drug discovery, through the use of strategies to delay the development of resistance. The purpose of this 
brief review is to underline the usefulness of SBDD approaches based on case studies, highlighting present challenges and opportunities 
in drug design. 
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INTRODUCTION 
 Drug discovery is a complex, costly and time-consuming proc-
ess. In addition to the usual hurdles faced in the design of small 
molecule drug candidates, the development of antimicrobial, antivi-
ral and anticancer agents involves an additional challenge: the rapid 
rise of drug resistance [1, 2]. At the molecular level, several mecha-
nisms have been associated with resistance. Given that the targets 
of these therapies are quickly proliferating cells, there is a high 
likelihood that mutations will occur. Another possibility is the 
upregulation of the target, making it necessary to increase drug 
concentrations to maintain efficacy. In addition, often drugs can be 
inactivated by chemical modifications, such as oxidation, chemical 
hydrolysis and conjugation. The drug concentration at the site of 
action can also be reduced due to efflux pumps [3-6]. 
 This problem is aggravated by the fact that while resistance 
quickly develops after a drug enters the clinic, developing a new 
drug is a much harder and slower process. Furthermore, very few 
medicines have been recently discovered in some areas in which 
drug resistance is common, such as antimicrobial therapy [1]. It is 
therefore of surmount importance to understand drug resistance 
mechanisms and to develop drug design strategies which can rescue 
the activity of known drugs or that are robust to target mutations [2, 
6, 7]. In this brief review, we highlight structure-based drug design 
(SBDD) approaches that are currently applied to overcome and 
avoid resistance to drug therapy. 
 The use of SBDD approaches has a long and rich history in 
drug discovery [8-13]. Structural information about the molecular 
target can aid either the discovery of new inhibitors through virtual 
screening [14-16], or the optimization of known ligands [11, 17]. 
Herein we present case studies that illustrate important strategies in 
which SBDD play an essential role to overcome drug resistance. By 
knowing the structure of mutant proteins, crucial differences be-
tween the wild type protein and the resistance mutant can be ex-
ploited, so that the mutants can be directly targeted. Additionally, 
inhibitors can be designed to avoid or at least delay the rise of  
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resistance, for example by exploiting interactions which are essen-
tial for interaction with the substrate, in such way that the rise of 
resistance would cost lost in function and therefore become un-
likely. There are also strategies that, instead of focusing on the 
original target of the drug, focus on targeting other resistance 
mechanisms, i.e. efflux pumps or enzymes that chemically inacti-
vate the drug. Such strategies yield drugs for combination therapies 
(Fig. 1). In addition to presenting the strategies above, we discuss 
some of the challenges and perspectives in the field. 
TARGETING MUTATED PROTEINS 
 The development of small-molecule modulators that target mu-
tated proteins is probably the most straightforward SBDD approach 
to overcome drug resistance. In cases where structures of resistant 
mutants are known, new drugs can be designed to bind not only to 
the wild-type target, but also to the mutants. Several examples have 
been described for this commonly employed strategy, in anticancer 
[18], antiviral [19] and antimicrobial therapy [20, 21]. A recent and 
interesting example was the development of new kinase inhibitors 
to overcome imatinib resistance. 
 The development of imatinib represents a major advance for the 
treatment of chronic myeloid leukemia (CML). This drug targets 
the ATP binding site in Abl, inhibiting this kinase by binding to its 
inactive conformation and stabilizing it. In spite of its efficacy, 
clinical resistance has been observed soon after its release. In the 
first reports, a now widely known mutation of the gatekeeper resi-
due Thr315 to an Ile was detected [22]. In this case, knowledge of 
the crystal structure of the complex provided an explanation for 
resistance: the side chain of Thr315 makes a hydrogen bond to 
imatinib, while in the Ile mutant this interaction is lost (Fig. 2) [23]. 
This discovery was followed by other findings of resistant clinical 
isolates containing several different mutations, which either change 
the dynamic of the kinase flexibility, impairing its ability to adopt 
the inactive conformation to which imatinib binds, or disrupt pro-
tein-drug interactions [5, 24]. The importance of this clinical issue 
motivated the development of a second generation of inhibitors 
[24]. Based on crystal structures of complexes between imatinib 
(and other kinase inhibitors) and the wild-type and mutant Bcr-Abl 
[23, 25], the use of SBDD approaches led to the development of 
nilotinib, an inhibitor 10 to 50-fold more potent than the original 
drug [18]. Nilotinib has proven to be efficacious against most of the 
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imatinib-resistant CML isolates, except for those containing the 
T315I gatekeeper mutation (for which most of the available drugs 
do not work) [26, 27]. In addition to the improved profile against 
mutants, recent clinical trials also revealed the potential of the drug 
for long-term CML treatment compared to imatinib [28, 29].  
 Even with the success of nilotinib, the high frequency of the 
T315I mutation encouraged the development of new agents against 
this protein. As observed in the case of nilotinib, several other com-
pounds were active against all mutant strains, except T315I. To 
overcome the resistance caused by the T315I mutation, successful 
approaches included the evaluation of inhibitors of other tyrosine 
kinases which either exploit other binding sites of the enzyme or 
bind in a different region of the (imatinib) ATP binding site.  
 The Aurora kinase inhibitor tozarsetib (MK-0457, VX-680) was 
active against this mutant strain and in CML patients bearing this 
mutation, presenting a tolerable safety profile [30-32]. The crystal 
structure of this compound bound to Bcr-Abl allowed the under-
standing of the intermolecular interactions and activity against the 
T315I mutant. While in the case of imatinib the interaction with 
Thr315 allows one of two essential hydrogen bonds between pro-
tein and ligand, molecular modeling studies of tozarsetib suggested 
that it would form only a weak hydrogen bond to this residue, while 
forming other five hydrogen-bonds to the protein (Fig. 2). In addi-
tion, this inhibitor binds to the enzyme active conformation [31]. 
The structural studies were useful for the understanding of the main 
binding requirements, and therefore, for further structure-based 
drug design efforts towards the identification of ligands having 
improved affinity and potency [23, 33].  
 Another strategy to overcome imatinib resistance consists in 
combining ATP binding site inhibitors with allosteric inhibitors. 
The first compounds that act through this mechanism (GNF-2 and 
GNF-5) were identified by experimental screening [34]. Later, 
structural studies revealed that they bind in the myristate binding 
site. These compounds were able to overcome resistance of several 
imanitib-resistant CML cells, and when combined with nilotinib 
were also effective against the T315I mutation. Moreover, it was 
shown that resistance is less likely to arise if a combination of 
GNF-2 and imatinib is used. In addition to showing the clinical 
potential of this class of compounds, especially when combined 
with ATP-competitive inhibitors, this study revealed the binding 
mode of the compounds, providing a molecular basis for further 
SBDD efforts [35]. Further SAR investigations led to the develop-
ment of a new class of nanomolar allosteric inhibitors of Bcr-Abl 
[36]. Together, these studies foster the design of drugs that act 
through this mechanism. 
DRUGS WITH A DUAL MECHANISM OF INHIBITION 
 A promising strategy to overcome or avoid the rise of drug 
resistance is to identify compounds that bind to more than one tar-
get. This approach has proven useful for the development of drugs 
for imatinib-resistant CML strains, through the design of dual in-
hibitors of Bcr-Abl and Src kinases. Src kinases are activated by 
Bcr-Abl and involved in multiple oncogenic pathways. Therefore, 
inhibition of both steps of the pathway should provide a beneficial 
effect. Given the similarity between these kinases, it is viable to 
design inhibitors effective against both, such as the drug dasatinib, 
a picomolar ATP-competitive inhibitor of both enzymes. The crys-
tal structure of this inhibitor in complex with Bcr-Abl has been 
reported, whereas the molecular docking of the compound against 
Scr suggests a similar binding mode [7, 37]. As observed with 
nilotinib, dasatinib was active against most imatinib-resistance 
strains, except to T315I [38]. The crystal structure of dasatinib 
bound to the Abl kinase domain revealed that the inhibitor binds to 
multiple conformational states of this kinase, while imatinib re-
quires the inactive conformation [39]. 
 Other examples of dual Abl/Src kinase inhibitors are the com-
pounds bosutinib (SKI-606) and bafetinib (INNO-406, NS-187). 
Bosutinib is effective against CML cells in animal models [40], and 
in phase II clinical trials in patients with imatinib resistance CML 
with all Bcr-Abl mutations, except T315I [41]. The development of 
bafetinib provided another classic example of SBDD. Examination 
of the Abl-imatinib crystal structure revealed a hydrophobic pocket 
close to the region where imatinib binds, which was explored lead-
ing to the design of bafetinib. This compound is a specific inhibitor 
of Abl and Lyn kinases, and is effective against 12 of the 13 muta-
tion strains evaluated, but T315I [42-44]. 
Fig. (1). SBDD strategies to overcome or avoid drug resistance.
a
b
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TARGETING SPECIFIC PROTEINS THAT LEAD TO 
DRUG RESISTANCE 
 In many cases, resistance emerges due to other mechanisms of 
resistance (not related to protein mutations) that turn the original 
drug ineffective. Thus, targeting the resistance mechanism allows 
the development of new medicines to be used in combination to the 
original drug. SBDD approaches are also useful in these cases. A 
classic example is the development of –lactamase inhibitors [6]. 
–lactamase is known as the main cause of bacterial resistance to 
penicillins, due to its ability to hydrolyze the –lactam ring, leading 
to the inactivation of the these drugs. There are several classes of –
lactamases (A, B, C and D) organized according to their structural 
and mechanistic similarities. To overcome resistance, there have 
been intense efforts to develop either penicillins that cannot be 
cleaved by these enzymes, or –lactamase inhibitors. In the latter 
case, even though the antimicrobial activity of these inhibitors is 
low, they are able to rescue the efficacy of other drugs. Clavulanate, 
sulbactam and tazobactam, used in combination with penicillins, 
are examples of drugs which act through this mechanism. While 
clavulanic acid was isolated from Streptomyces clavuligerus in the 
1970s, sulbactam and tazobactam were developed as analogues. An 
important limitation of these compounds is the limited spectrum, 
especially for their lack of efficacy against class C –lactamases. 
 Throughout three decades of development of –lactamase in-
hibitors, hundreds of crystal structures (in the apo form or bound to 
different inhibitors) made possible a deep understanding of the 
mechanisms of inhibition involved [6]. Several SBDD efforts were 
made to allow the discovery of potent inhibitors (lactams and non-
lactams, Fig. 3), including the use of virtual screening of compound 
libraries [15, 45, 46] and structure-guided optimization [47-51]. 
 The development of bridged monobactams and sulfactams is a 
good example of the application of structure-based drug design. An 
analysis of the crystal structure of Citrobacter freundii 1203 -
lactamase in complex with aztreonam suggested the importance of a 
conformational change in the inhibitor to allow the hydrolysis of 
the acyl-enzyme intermediate. Based on that, bridged compounds 
were designed aiming to hinder the conformational change neces-
sary for hydrolysis, leading to the discovery of a class C -
lactamase inhibitors with very slow hydrolysis rates. In addition, 
these compounds were able to reduce up to 200-fold the minimum 
inhibitory concentration (MIC) of ceftriaxone [52]. Further studies 
led to a bridged sulfactam, which was an effective inhibitor against 
both class A and C -lactamase [55]. Similarly, tryciclic carbap-
enems were designed to displace a water molecule involved in the 
deacylation step, preventing antimicrobial hydrolysis and resulting 
in class C –lactamase inhibitors [53, 56].  
 A concern with -lactam inhibitors is that they frequently 
upregulate -lactamase, which in turn affects their efficacy. There-
fore, there is a high interest in the development of non -lactams 
inhibitors. To this end, SBDD efforts led to the identification of 
boronic acids as tetrahedral reaction analogues. Several AmpC –
lactamase inhibitors with Ki in the low nanomolar range have been 
reported, while crystal structures of enzyme-inhibitor complexes 
have provided valuable insights for drug design. Furthermore, the 
inhibitors were shown to decrease MIC of penicillins, without 
upregulation of -lactamase [47-50, 57-59]. Several other chemical 
classes were discovered by virtual screening and later optimized by 
SBDD, leading to low micromolar –lactamase inhibitors that do 
not upregulate –lactamase expression [54, 60]. Virtual screening 
studies also resulted in the identification of phthalimide inhibitors 
[61] and several families of fragments that inhibit AmpC [15] or 
CTX-M –lactamase [46], providing compounds for lead discovery 
and optimization. 
 Aminoglycosides are antimicrobials that lose efficacy due to 
chemical modifications, such as phosphorylation, acetylation and 
adenylylation [62]. Several of the enzymes that chemically modify 
these drugs are known, and can be potential targets for drug devel-
opment. Some acetyltransferases can also inactivate other classes of 
antimicrobials, such as quinolones, increasing their clinical rele-
vance [4, 63]. Among the amynoglycoside modifying enzymes, 
aminoglycoside transferase type III (APH3’-III3a) is a common 
resistance factor, widely studied and responsible for the phosphory-
lation of several antibiotics in the class [64]. The determination of 
the crystal structure of this kinase revealed strong similarities to 
eukariotic protein kinases [65], motivating the evaluation of inhibi-
tors of human kinases against this enzyme and APH(2’’), which 
confers resistance to most aminoglycosides, leading to the discov-
ery of inhibitors [66]. Later, structures of complexes of one of these 
inhibitors with APH3’-III3a revealed differences to the binding 
mode observed against the eukaryotic protein kinases, suggesting 
that selectivity against the aminoglycoside transferases can be 
achieved [67]. In addition, recent structural studies of complexes 
between APH(2”) and aminoglycosides provided insights into drug 
modifications which would be poorly tolerated by the enzyme, 
being helpful in the design of the next generation of aminoglyco-
sides [68]. Structures of other aminoglycoside phosphotransferases, 
acetyltransferases and adenylyltranferases have also been deter-
mined, providing a more solid basis for SBDD against these en-
zymes [69-72].  
 Another common mechanism of antimicrobial resistance is the 
reduction of drug concentrations in the bacteria due to efflux 
pumps, some of which are highly promiscuous and can cause multi-
drug resistance (MDR) [3, 73-75]. Therefore, inhibiting the activity 
of these pumps can potentially rescue the activity of multiple drugs, 
as exemplified by compounds that rescue activity of antitumor [76-
78] and antimicrobial drugs. These perspectives motivated studies 
to understand the MDR efflux pump mechanism, and to discover 
Fig. (2). Structural basis for the activity of tozarsetib against the T315I mutant. Binding modes of (a) imatinib (PDB code 2HYY) and (b) tozarsetib (PDB 
code 2F4J) in the active site of Bcr-Abl kinase. While imatinib makes a hydrogen bond (green dashed line) to Thr315 (highlighted as sticks), tozarsetib does 
not interact with this residue and binds to a different region in the active site. 
a b
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binding sites for drug development. An example is the determina-
tion of crystal structures of the AcrB pump in the presence or ab-
sence of substrates, which allowed the identification of a binding 
site [79, 80]. Later, complexes with other antimicrobials demon-
strated the existence of another binding pocket, which could ac-
commodate larger ligands. Together, these studies allowed a better 
understanding of the mechanism of this efflux pump, leading to the 
characterization of two multidrug binding sites for drug discovery 
[81]. 
ESSENTIAL SUBSTRATE INTERACTIONS TO AVOID 
THE DEVELOPMENT OF RESISTANCE 
 An important limitation of the approaches described so far is 
that they are frequently a step behind. First, resistance has to arise, 
next, the mechanism involved has to be understood, and then, new 
agents can be developed. Consequently, uncovering new mecha-
nisms of drug resistance is only the first step in the long process of 
developing more effective drugs. A new approach involving the 
design of drugs for which resistance is less likely to arise would 
change the current scenario. To this end, it has been successfully 
described the design of inhibitors that interact with regions of the 
protein less likely to mutate, such as residues which are essential 
for the function of the target. The development of HIV protease 
inhibitors illustrates two of such approaches: the design of com-
pounds based on the substrate envelope hypothesis or that strongly 
interact with the protein backbone.  
 The rationale behind the first approach is straightforward. If the 
inhibitors occupy a region in the active site that coincides with the 
consensus occupied by the substrates, drug resistance is less likely 
to occur, since mutations that lead to drug resistance would be det-
rimental to the protease activity. This common volume occupied by 
different substrates is defined as the substrate envelope. Indeed, it 
has been observed that resistant mutations in HIV protease inhibi-
tors are observed for residues that do not contact its substrate, and 
are localized where inhibitors protrude from such envelope [82, 83]. 
Nano- and picomolar HIV protease inhibitors that satisfy the sub-
strate envelope constraints have been described [84]. Importantly, 
potent inhibitors that were developed based on this hypothesis in-
deed showed a flatter activity against a panel of resistance mutants, 
whereas compounds that protruded the substrate envelope usually 
were less potent against the mutant proteins [85]. This definition 
has been recently modified to include protein dynamics [86]. The 
substrate envelope hypothesis has also been shown to agree with 
data for a series of HCV protease inhibitors. As observed for the 
HIV protease inhibitors, compounds for which resistance is more 
common protrude from the substrate envelope volume [87]. Corre-
lation studies performed for several targets suggest that this concept 
can be applied in a more general way to design enzyme inhibitors. 
A retrospective analysis for inhibitors of anticancer, antiviral and 
antimicrobial enzymes, revealed that resistance is less common for 
compounds that occupy only the consensus volume of the respec-
tive substrate envelope [88].  
 A similar approach, based on the development of inhibitors 
which optimize interactions with the HIV protease backbone, led to 
the development of darunavir, an FDA approved drug for AIDS 
therapy. Initially, the alignment of several resistant mutant struc-
tures revealed that only minimal changes were observed in the pro-
tein backbone. Therefore, given that mutations usually do not affect 
interactions with the protein backbone, the optimization of these 
interactions would lead to a decreasing of its ability to create resis-
tant mutants. The optimization of the lead compound allowed the 
development of darunavir, an antiviral with remarkable potency 
against HIV strains resistant to several other HIV protease inhibi-
tors (Fig. 4) [89]. It is interesting to note that, even though darun-
avir was not developed based on the substrate envelope hypothesis, 
it fits the consensus substrate volume [90]. Recent reports demon-
strated the development of novel potent antiviral compounds, with a 
better profile against resistance mutants compared with that of da-
runavir, which exploited additional hydrogen bonds to the protein 
backbone [19, 91]. 
Fig. (3). Different classes of -lactamase inhibitors. A) drugs currently used in the clinic; b) examples of other -lactam inhibitors: (1) a bridged monobactam 
[52], (2) a bridged sulfactam [51], (3) a trinem [53]; c) examples of non -lactams inhibitors: (4) a boronic acid [47]; (5) a sulfonamide inhibitor [54]. 
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Fig. (4). Binding mode of darunavir in the HIV protease active site (PDB 
code 4DQB). Dashed lines indicate hydrogen bonds to the backbone (green) 
or to side chains or water (orange).  
CONCLUSION 
 The threat of drug resistance is becoming uncomfortably close 
to reality for a growing number of therapeutic classes, representing 
a major challenge for the pharmaceutical industry. There is an ur-
gent need for novel treatments aimed at combating the rapid rise in 
drug resistance. The use of modern SBDD approaches has proven 
successful in a number of cases to combat drug resistance, as dem-
onstrated by the cases reviewed here. Given the extreme importance 
of this field and the successes obtained so far, it is expected that 
structural information will be increasingly more applied in this area. 
The application of several different strategies has strong relevance, 
as it will allow us to evaluate which approaches are more successful 
and prioritize strategies to be employed in different circumstances. 
It is important to keep in mind that even when a drug is designed to 
avoid the rise of resistance, it may exhibit a variety of problems. 
For some of the agents that have been effectively designed to be 
resistant to mutations, the emergence of new mutants (not sensitive 
to the drug) may occur, posing serious danger to the treatment. 
These facts are related to economic and health concerns, which 
directly affects the cost, uncertainty and returns of pharmaceutical 
R&D, and may have dramatic impact on future investments.  
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